ZS Pharma Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial Evaluating ZS-9 for the Treatment of Hyperkalemia
Published: Oct 23, 2013
COPPELL, Texas--(BUSINESS WIRE)--ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular, and liver disorders, announced that it has completed enrollment in its Phase 3 pivotal trial (ZS-003) evaluating the ability of ZS-9 to treat hyperkalemia. Hyperkalemia is a life-threatening condition that is characterized by higher than normal levels of potassium (K+) in the blood serum. Underlying causes of hyperkalemia include chronic kidney disease, heart failure, diabetes, and cardio-renal protective RAAS inhibitor therapies, such as ACEs, ARBs and aldosterone blockers.
Help employers find you! Check out all the jobs and post your resume.